Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Down 85.8% in October

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) saw a significant decrease in short interest in October. As of October 31st, there was short interest totalling 15,600 shares, a decrease of 85.8% from the October 15th total of 110,200 shares. Currently, 3.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 67,600 shares, the short-interest ratio is currently 0.2 days.

Qualigen Therapeutics Trading Down 8.4 %

Shares of NASDAQ QLGN traded down $0.36 during mid-day trading on Tuesday, reaching $3.93. The company had a trading volume of 51,081 shares, compared to its average volume of 94,118. Qualigen Therapeutics has a twelve month low of $3.75 and a twelve month high of $39.13. The stock’s 50 day moving average is $7.52 and its 200-day moving average is $10.43.

Qualigen Therapeutics (NASDAQ:QLGN) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($10.00) EPS for the quarter.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.